Relevance of Tokuhashi Score in Spinal Metastases Management in the Era of Molecular Biology: Focus on Lung Cancer
This study demonstrates that the Tokuhashi score has lost its prognostic accuracy for predicting survival in lung cancer patients with spinal metastases, whereas molecular status has emerged as a critical independent factor necessitating its integration into future management strategies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When cancer spreads from its original site to other parts of the body, it often finds a home in the bones, and the spine is a frequent destination. This invasion can cause severe pain, weaken the bones until they break, or press on the spinal cord, threatening a patient's ability to move or feel. For decades, doctors have needed a way to guess how long a patient might live after such a spread occurs, as this estimate helps decide whether to offer aggressive surgery or focus on comfort care. One of the most common tools for making this guess has been a scoring system called the Tokuhashi score. It looks at six factors, including how well a patient can perform daily tasks, how many bones are affected, and what type of cancer they have. For lung cancer, this system has traditionally assigned a very low score, suggesting a short remaining life, because lung cancer was once considered almost always fatal once it reached the bones. However, the landscape of lung cancer treatment has changed dramatically in recent years. New medicines, known as targeted therapies and immunotherapies, can stop specific cancer cells from growing or help the body's immune system fight the disease, allowing many patients to live much longer than doctors previously expected.
A team of researchers in France set out to see if the old scoring system still works in this new era of modern medicine. They looked back at the records of 804 patients who had been discussed by a group of specialists to decide on treatment for spinal metastases between 2007 and 2019. Of these, 220 patients had lung cancer. The researchers calculated the Tokuhashi score for each of these patients and also checked if they had any specific molecular changes in their cancer cells. These changes are like unique genetic switches that drive the cancer's growth, and identifying them allows doctors to use drugs designed specifically to block those switches. The team then tracked how long each patient survived after the diagnosis of spinal metastasis.
The results showed that the old scoring system was failing to capture the reality of modern lung cancer care. When the researchers applied the Tokuhashi score to their group of lung cancer patients, nearly all of them, about 91 percent, fell into the "poor prognosis" category. According to the rules of the score, these patients were expected to have a very short time left to live. Yet, when the researchers looked at the actual survival data, the score did not match the outcome. The system could not distinguish between patients who would survive only a few months and those who would live much longer. In fact, the researchers found no significant link between the Tokuhashi score and how long the patients actually lived.
Instead, the key to predicting survival lay in the molecular biology of the tumor. The researchers found that patients whose cancer had a specific molecular alteration that could be targeted with medicine lived significantly longer than those who did not. The patients with these treatable molecular changes had a median survival of 10.22 months, meaning half of them lived longer than this time. In contrast, patients without these specific molecular markers had a median survival of only 3.61 months. This difference was stark and statistically clear. Even when the researchers adjusted for all the other factors the Tokuhashi score uses, such as the number of affected bones or the patient's general health, the presence of a treatable molecular change remained a powerful, independent predictor of a longer life.
The study suggests that the Tokuhashi score is no longer accurate for lung cancer patients with spinal metastases because it treats all lung cancer as the same, ignoring the life-extending potential of modern targeted drugs. By continuing to rely on a system that labels nearly all lung cancer patients as having a poor outlook, doctors might be missing the opportunity to offer more aggressive and potentially beneficial local treatments, such as surgery or specialized radiation, to the subgroup of patients who could actually live for a year or more. The researchers conclude that future tools for predicting survival must include molecular profiling to give a true picture of a patient's chances, ensuring that treatment decisions are based on the specific biology of the cancer rather than an outdated generalization.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.